Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Biomea Fusion, Inc. - Common Stock (NQ:BMEA)

1.360 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	9,361
Open	1.360
Bid (Size)	1.340 (100)
Ask (Size)	1.400 (8,000)
Prev. Close	1.360
Today's Range	1.360 - 1.360
52wk Range	0.8719 - 2.990
Shares Outstanding	35,631,576
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

June 05, 2026

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

June 03, 2026

From Biomea Fusion, Inc.

Via GlobeNewswire

Performance

YTD	+1.5%	+1.5%
1 Month	-2.2%	-2.2%
3 Month	-8.7%	-8.7%
6 Month	+9.7%	+9.7%
1 Year	-20.9%	-20.9%

More News

Biomea Fusion Inc (NASDAQ:BMEA) Q1 2026 Earnings Beat and Pipeline Progress Drive Cautious Optimism ↗

May 11, 2026

Via Chartmill

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

May 11, 2026

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

May 05, 2026

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

April 27, 2026

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

March 31, 2026

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights

March 24, 2026

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib ↗

March 14, 2026

Via Benzinga

Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026

March 14, 2026

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion to Participate at Upcoming Investor Conferences

February 19, 2026

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones

January 12, 2026

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 17, 2025

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025

December 09, 2025

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

December 05, 2025

From Biomea Fusion, Inc.

Via GlobeNewswire

Which stocks are moving after the closing bell on Tuesday? ↗

December 02, 2025

Via Chartmill

Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

December 01, 2025

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

December 01, 2025

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion to Participate at Upcoming Investor Conferences

November 24, 2025

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion to Participate at Jefferies London Healthcare Conference

November 10, 2025

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025

November 05, 2025

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights

November 04, 2025

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion to Present Poster Presentations at ObesityWeek®2025

October 30, 2025

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist

October 27, 2025

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series

October 21, 2025

From Biomea Fusion, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Biomea Fusion, Inc. - Common Stock publicly traded?

Yes, Biomea Fusion, Inc. - Common Stock is publicly traded.

What exchange does Biomea Fusion, Inc. - Common Stock trade on?

Biomea Fusion, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Biomea Fusion, Inc. - Common Stock?

The ticker symbol for Biomea Fusion, Inc. - Common Stock is BMEA on the Nasdaq Stock Market

What is the current price of Biomea Fusion, Inc. - Common Stock?

The current price of Biomea Fusion, Inc. - Common Stock is 1.360

When was Biomea Fusion, Inc. - Common Stock last traded?

The last trade of Biomea Fusion, Inc. - Common Stock was at 07/01/26 04:00 PM ET

What is the market capitalization of Biomea Fusion, Inc. - Common Stock?

The market capitalization of Biomea Fusion, Inc. - Common Stock is 48.46M

How many shares of Biomea Fusion, Inc. - Common Stock are outstanding?

Biomea Fusion, Inc. - Common Stock has 48M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.